Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sagent Pharmaceuticals Inc (NASDAQ:SGNT)

21.68
Delayed Data
As of 11:57am ET
 +0.04 / +0.18%
Today’s Change
10.55
Today|||52-Week Range
25.86
+36.27%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$710.6M

Company Description

Sagent Pharmaceuticals, Inc. is a pharmaceutical company, which focuses on developing, manufacturing, sourcing and marketing pharmaceutical products. Its primary focus on generic injectable pharmaceuticals, which provide customers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes and premix bags. The company operates through following segments: Sagent U.S. and Omega. The Sagent U.S. segment consists of U.S. operations and the SCP manufacturing facility. The Omega segment focuses on the Canadian and international markets. Sagent Pharmaceuticals was founded by Jeffrey M. Yordon on January 26, 2006 and is headquartered in Schaumburg, IL.

Contact Information

Sagent Pharmaceuticals, Inc.
1901 North Roselle Road
Schaumburg Illinois 60195
P:(847) 908-1600
Investor Relations:
(847) 908-1605

Employees

Shareholders

Individual stakeholders53.74%
Other institutional43.01%
Mutual fund holders38.76%

Top Executives

Allan ObermanChief Executive Officer & Director
J. Frank HarmonExecutive Vice President-Global Operations
Jonathon M. SingerChief Financial Officer & Executive Vice President
Jeffrey W. GreveVice President & Controller
Sean BrynjelsenExecutive Vice President-Business Development